Stem definition | Drug id | CAS RN |
---|---|---|
4188 | 30652-11-0 |
None
None
Date | Agency | Company | Orphan |
---|---|---|---|
Aug. 25, 1999 | EMA | APOTEX EUROPE BV | |
Oct. 14, 2011 | FDA | APOPHARMA INC |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Agranulocytosis | 264.31 | 34.48 | 65 | 894 | 23684 | 53324423 |
Sickle cell anaemia with crisis | 153.81 | 34.48 | 31 | 928 | 4496 | 53343611 |
Neutropenia | 80.01 | 34.48 | 44 | 915 | 159141 | 53188966 |
Serum ferritin increased | 60.37 | 34.48 | 15 | 944 | 5549 | 53342558 |
Death | 34.71 | 34.48 | 37 | 922 | 357195 | 52990912 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Agranulocytosis | 156.73 | 30.35 | 46 | 763 | 23431 | 32489286 |
Neutropenia | 56.50 | 30.35 | 38 | 771 | 142137 | 32370580 |
Sickle cell anaemia with crisis | 45.60 | 30.35 | 11 | 798 | 2598 | 32510119 |
Death | 45.23 | 30.35 | 51 | 758 | 382466 | 32130251 |
Serum ferritin increased | 32.13 | 30.35 | 10 | 799 | 6069 | 32506648 |
Source | Code | Description |
---|---|---|
ATC | V03AC02 | VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Iron chelating agents |
FDA MoA | N0000000144 | Iron Chelating Activity |
FDA EPC | N0000175522 | Iron Chelator |
MeSH PA | D002614 | Chelating Agents |
MeSH PA | D007502 | Iron Chelating Agents |
MeSH PA | D064449 | Sequestering Agents |
CHEBI has role | CHEBI:38157 | iron chelators |
CHEBI has role | CHEBI:50267 | protective agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Iron overload | indication | 60737008 | |
beta Thalassemia | indication | 65959000 | DOID:12241 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.54 | acidic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
100MG/ML | FERRIPROX | CHIESI | N208030 | Sept. 9, 2015 | RX | SOLUTION | ORAL | 8703156 | Oct. 26, 2029 | METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD |
80MG/ML | FERRIPROX | CHIESI | N208030 | April 20, 2018 | DISCN | SOLUTION | ORAL | 8703156 | Oct. 26, 2029 | METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD |
1GM | FERRIPROX | CHIESI | N212269 | May 19, 2020 | RX | TABLET | ORAL | 10780055 | Oct. 25, 2038 | METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD |
1GM | FERRIPROX | CHIESI | N212269 | May 19, 2020 | RX | TABLET | ORAL | 10940115 | Oct. 25, 2038 | METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
1GM | FERRIPROX | CHIESI | N021825 | July 25, 2019 | RX | TABLET | ORAL | April 30, 2024 | TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO SICKLE CELL DISEASE OR OTHER ANEMIAS |
500MG | FERRIPROX | CHIESI | N021825 | Oct. 14, 2011 | RX | TABLET | ORAL | April 30, 2024 | TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO SICKLE CELL DISEASE OR OTHER ANEMIAS |
100MG/ML | FERRIPROX | CHIESI | N208030 | Sept. 9, 2015 | RX | SOLUTION | ORAL | April 30, 2024 | TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO SICKLE CELL DISEASE OR OTHER ANEMIAS |
80MG/ML | FERRIPROX | CHIESI | N208030 | April 20, 2018 | DISCN | SOLUTION | ORAL | April 30, 2024 | TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO SICKLE CELL DISEASE OR OTHER ANEMIAS |
1GM | FERRIPROX | CHIESI | N212269 | May 19, 2020 | RX | TABLET | ORAL | April 30, 2024 | TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO SICKLE CELL DISEASE OR OTHER ANEMIAS |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Deoxyhypusine hydroxylase | Enzyme | IC50 | 5.30 | CHEMBL |
ID | Source |
---|---|
4031179 | VUID |
N0000183921 | NUI |
D07416 | KEGG_DRUG |
4031179 | VANDF |
C0043832 | UMLSCUI |
CHEBI:68554 | CHEBI |
CHEMBL70927 | ChEMBL_ID |
D000077543 | MESH_DESCRIPTOR_UI |
DB08826 | DRUGBANK_ID |
7456 | IUPHAR_LIGAND_ID |
6958 | INN_ID |
2BTY8KH53L | UNII |
2972 | PUBCHEM_CID |
11645 | RXNORM |
117386 | MMSL |
18035 | MMSL |
51626 | MMSL |
d04976 | MMSL |
007561 | NDDF |
329482000 | SNOMEDCT_US |
396011004 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Deferiprone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0576 | TABLET, COATED | 500 mg | ORAL | ANDA | 28 sections |
Deferiprone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0711 | TABLET, COATED | 1000 mg | ORAL | ANDA | 28 sections |
FERRIPROX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10122-100 | TABLET, FILM COATED | 500 mg | ORAL | NDA | 28 sections |
FERRIPROX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10122-100 | TABLET, FILM COATED | 500 mg | ORAL | NDA | 28 sections |
FERRIPROX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10122-101 | SOLUTION | 100 mg | ORAL | NDA | 29 sections |
FERRIPROX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10122-103 | TABLET, FILM COATED | 1000 mg | ORAL | NDA | 28 sections |
FERRIPROX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10122-104 | TABLET | 1000 mg | ORAL | NDA | 28 sections |
Deferiprone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51672-4196 | TABLET | 500 mg | ORAL | ANDA | 31 sections |
FERRIPROX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52609-0006 | TABLET, FILM COATED | 500 mg | ORAL | NDA | 28 sections |
FERRIPROX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52609-0007 | TABLET, FILM COATED | 1000 mg | ORAL | NDA | 29 sections |
FERRIPROX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52609-4502 | SOLUTION | 100 mg | ORAL | NDA | 29 sections |